Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.59 |
| ▸ | KMO | O15229 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184435 | 0.88 | TSHR (0.70) | TSHRSRD5A2KMOMEN1KMT2A | |
| SCHEMBL11655118 | 0.85 | TSHR (0.61) | TSHRSRD5A2KMOMEN1KMT2A | |
| SCHEMBL7608864 | 0.83 | TSHR (0.47) | TSHRSRD5A2KDM4ENPC1MAPT | |
| SCHEMBL28814684 | 0.83 | CES2 (0.63) | TSHRSRD5A2NPC1RAB9A | |
| SCHEMBL7831951 | 0.83 | HSP90AA1 (0.51) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL728169 | 0.82 | TSHR (0.57) | TSHRSRD5A2KMOMEN1KMT2A | |
| SCHEMBL8352471 | 0.81 | TSHR (1.00) | TSHRSRD5A2KMOMEN1KMT2A | |
| SCHEMBL371998 | 0.81 | TSHR (1.00) | TSHRSRD5A2KMOMEN1KMT2A | |
| SCHEMBL29353637 | 0.81 | TSHR (1.00) | TSHRSRD5A2KMOMEN1KMT2A | |
| SCHEMBL15137054 | 0.81 | CES2 (0.52) | TSHRMEN1KMT2ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111662202-B | Synthetic method of alpha-ketoamide compound | 五邑大学 | 2022-09-30 | — | — | CN | disclosed |
| CN-111662202-A | Synthetic method of alpha-ketoamide compound | 五邑大学 | 2020-09-15 | — | — | CN | disclosed |
| US-7893066-B2 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | GILEAD PALO ALTO, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2276748-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009126123-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20080255130-A1 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
| EP-1423119-A4 | HETEROBICYCLES FKBP-LIGANDS | AGOURON PHARMA (US) | 2005-04-13 | — | — | EP | disclosed |
| EP-1423119-A1 | HETEROBICYCLES FKBP-LIGANDS | Agouron Pharmaceuticals, Inc. (US) | 2004-06-02 | — | — | EP | disclosed |
| WO-2002089806-A1 | HETEROBICYCLES FKBP-LIGANDS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255130-A1 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | SCD, SCD5, FASN | TSHR 4165/4885SRD5A2 182/4885KMO 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.